JCI Insight (Apr 2022)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
- Ane Ogbe,
- Matthew Pace,
- Mustapha Bittaye,
- Timothy Tipoe,
- Sandra Adele,
- Jasmini Alagaratnam,
- Parvinder K. Aley,
- M. Azim Ansari,
- Anna Bara,
- Samantha Broadhead,
- Anthony Brown,
- Helen Brown,
- Federica Cappuccini,
- Paola Cinardo,
- Wanwisa Dejnirattisai,
- Katie J. Ewer,
- Henry Fok,
- Pedro M. Folegatti,
- Jamie Fowler,
- Leila Godfrey,
- Anna L. Goodman,
- Bethany Jackson,
- Daniel Jenkin,
- Mathew Jones,
- Stephanie Longet,
- Rebecca A. Makinson,
- Natalie G. Marchevsky,
- Moncy Mathew,
- Andrea Mazzella,
- Yama F. Mujadidi,
- Lucia Parolini,
- Claire Petersen,
- Emma Plested,
- Katrina M. Pollock,
- Thurkka Rajeswaran,
- Maheshi N. Ramasamy,
- Sarah Rhead,
- Hannah Robinson,
- Nicola Robinson,
- Helen Sanders,
- Sonia Serrano,
- Tom Tipton,
- Anele Waters,
- Panagiota Zacharopoulou,
- Eleanor Barnes,
- Susanna Dunachie,
- Philip Goulder,
- Paul Klenerman,
- Gavin R. Screaton,
- Alan Winston,
- Adrian V.S. Hill,
- Sarah C. Gilbert,
- Miles Carroll,
- Andrew J. Pollard,
- Sarah Fidler,
- Julie Fox,
- Teresa Lambe,
- John Frater
Affiliations
- Ane Ogbe
- Matthew Pace
- Mustapha Bittaye
- Timothy Tipoe
- Sandra Adele
- Jasmini Alagaratnam
- Parvinder K. Aley
- M. Azim Ansari
- Anna Bara
- Samantha Broadhead
- Anthony Brown
- Helen Brown
- Federica Cappuccini
- Paola Cinardo
- Wanwisa Dejnirattisai
- Katie J. Ewer
- Henry Fok
- Pedro M. Folegatti
- Jamie Fowler
- Leila Godfrey
- Anna L. Goodman
- Bethany Jackson
- Daniel Jenkin
- Mathew Jones
- Stephanie Longet
- Rebecca A. Makinson
- Natalie G. Marchevsky
- Moncy Mathew
- Andrea Mazzella
- Yama F. Mujadidi
- Lucia Parolini
- Claire Petersen
- Emma Plested
- Katrina M. Pollock
- Thurkka Rajeswaran
- Maheshi N. Ramasamy
- Sarah Rhead
- Hannah Robinson
- Nicola Robinson
- Helen Sanders
- Sonia Serrano
- Tom Tipton
- Anele Waters
- Panagiota Zacharopoulou
- Eleanor Barnes
- Susanna Dunachie
- Philip Goulder
- Paul Klenerman
- Gavin R. Screaton
- Alan Winston
- Adrian V.S. Hill
- Sarah C. Gilbert
- Miles Carroll
- Andrew J. Pollard
- Sarah Fidler
- Julie Fox
- Teresa Lambe
- John Frater
- Journal volume & issue
-
Vol. 7,
no. 7
Abstract
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
